Julien Torgue

Chief Scientific Officer OranoMed

Seminars

Wednesday 12th November 2025
Internalisation of Targeted Radiopharmaceuticals: Strategic Imperative or Situational Choice?
1:30 pm
  • DARPin optimizations to achieve an RLT suitable profile via iterative design – test cycles
  • Integrating of these insights for optimized lead selection of the next programs
  • How this differs from standard RLT vector development and allows to optimize timelines, costs, resources
Julien Torgue, Chief Scientific Officer, OranoMed